Johnson and Johnson acquired Momenta Pharmaceuticals, aims to strength immunology profile

Johnson and Johnson announced that it will acquire Momenta Pharmaceuticals for an all cash transaction worth of $6.5 billion.

Momenta Pharmaceuticals is involved developing novel therapies for immunological diseases.

Also read: Novartis Kesimpta approved for relapsing multiple sclerosis in the US

Also read: Japan's healthcare system

The transaction will help Janssen to retain the global rights for nipocalimab (M281), drug which can potentially target FcRn antibody. The drug is in the Phase 2/3 trial for autoimmune hemolytic anemia. The drug is the Phase 2 trials for haemolytic diseases of new born and myasthenia gravis. Janssen expects a peak sales of more than one billion for nipocalimab. Company’s other product M254 is in the Phase 2 trial for immune thrombocytopenic purpura (ITP), and in Phase 1 trial for chronic inflammatory demyelination polyneuropathy.

Also read: Amgen’s Kyprolis and Janssen’s Darzalex combination approved by the US FDA for multiple myeloma

Also read: AZ received one more approval in Japan, received approval of Imfinzi for SCLC

Momenta Pharmaceuticals has developed expertise in FcRn mechanism, as it is believed to support number of autoantibody-driven conditions. Myasthenia gravis, hemolytic diseases new born, warm autoimmune hemolytic anemia, and other serious dermatologic, rheumatic, neurologic, hematologic and renal diseases are common autoantibody-driven diseases.

Also read: US Healthcare System

With the acquisition, Janssen expects to expands its portfolio in maternal-fetal disorders neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology.

Janssen has announced that it will retain Momenta’s presence in Cambridge, Massachusetts.

Also read: Gilead’s CAR-T cell therapy approved for Relapsed or Refractory Mantle Cell Lymphoma


For pipeline, market overview, SLRs, and market access reports (syndicate and customised) please write to

For all syndicate reports: Click here